Medicenna Therapeutics (TSE:MDNA) Trading Down 1.7% - Here's What Happened

Shares of Medicenna Therapeutics Corp. (TSE:MDNA - Get Free Report) were down 1.7% during trading on Monday . The company traded as low as C$1.06 and last traded at C$1.13. Approximately 72,877 shares were traded during mid-day trading, an increase of 2% from the average daily volume of 71,481 shares. The stock had previously closed at C$1.15.

Medicenna Therapeutics Stock Up 3.0 %

The stock's fifty day moving average price is C$1.39 and its 200 day moving average price is C$1.82. The company has a current ratio of 11.40, a quick ratio of 4.65 and a debt-to-equity ratio of 0.88. The stock has a market cap of C$77.81 million, a P/E ratio of -2.86 and a beta of 1.21.

Insider Buying and Selling

In other news, Senior Officer David Hyman bought 20,000 shares of the business's stock in a transaction on Thursday, January 9th. The stock was acquired at an average price of C$1.45 per share, with a total value of C$29,000.00. 22.57% of the stock is owned by company insiders.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.